Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 3810944
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**BI 3810944** is a small molecule drug developed by Boehringer Ingelheim for the treatment of advanced solid tumors, including melanoma. It is currently in a first-in-human Phase 1 clinical trial (NCT07224425) evaluating safety, tolerability, dose escalation, and preliminary efficacy in patients with advanced cancers refractory to standard therapies or lacking approved treatments. The drug is administered intravenously, initially weekly for a short period then every 3 weeks, with treatment up to 2 years or until disease progression. Specific mechanism of action and target details are not publicly disclosed in available sources.[1][3][4]
Beyond the preview
Go deeper on BI 3810944.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 3810944.